Y-mAbs Announces Second Quarter Financial Results and Recent Corporate Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Y-mAbs Therapeutics (YMAB) Tops Q2 EPS by 11c
August 5, 2021 4:28 PM EDTY-mAbs Therapeutics (NASDAQ: YMAB) reported Q2 EPS of ($0.53), $0.11 better than the analyst estimate of ($0.64). Revenue for the quarter came in at $8.95 million versus the consensus estimate of $7.85 million.
We are very pleased with our second quarter 2021 results. The commercialization of DANYELZA® (naxitamab-gqgk) is... More
